FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587042212> ?p ?o ?g. }

• W2587042212 abstract "Abstract Abstract 2765 The first FDA-approved proteasome inhibitor (PI), bortezomib, has shown limited single-agent activity in DLBCL but has been approved for the treatment of refractory mantle cell lymphoma (MCL). These considerations prompted effects to improve PI activity in these disorders by developing newer-generation PIs or by combining PIs with other targeted agents. Histone deacetylase (HDAC) inhibitors are epigenetic agents that kill transformed cells through diverse mechanisms, including induction of oxidative injury and DNA damage, and have been approved for the treatment of CTCL. Moreover, HDAC inhibitors that disrupt HDAC6 function induce cell death by interfering with aggresome function and protein disposition. We previously reported that the irreversible proteasome inhibitor carfilzomib (CFZ; Onyx), recently approved for the treatment of refractory multiple myeloma, interacted synergistically with the pan-HDAC inhibitor vorinostat in ABC- and GC- DLBCL cells as well as MCL cells.(Dasmahapatra et al. Blood 2010; 115(22):4478-87; Dasmahapatra et al. Mol Cancer Ther 2011: 10(9):1686-97). The purpose of the present study was to determine whether the selective HDAC6 inhibitor ACY-1215 (Acetylon) potentiated CFZ activity in DLBCL and MCL cells, and if so, by what mechanisms. Knock-down of HDAC6 protein by shRNA rendered SUDHL4 cells significantly more sensitive to CFZ compared to scrambled sequence control cells. Simultaneous treatment (24–48 hr) with sub-lethal CFZ concentrations (2.5–6 nM) and minimally toxic concentrations of either ACY-1215 (2.0–4.0μM) or Tubastatin A (5.0–7.5 μM) strikingly increased apoptosis in multiple DLBCL ( SUDHL16, SUDHL4, OCI-LY10) and MCL cells (e.g. Granta and Rec-1). Interactions were highly synergistic by Median Dose Effect analysis, with Combination Index (CI) values significantly less than 1.0 (e.g. 0.4 – 0.6). Other PIs (e.g. MG132) and commercially available HDAC6 inhibitors (e.g., Tubastatin A) also interacted synergistically. The CFZ/ACY1215 regimen also strikingly induced apoptosis in a primary DLBCL sample (ABC sub-type), but was relatively non-toxic to normal CD34+ bone marrow cells. Enhanced activity was associated with a sharp increase in caspase-3 activation, PARP cleavage, mitochondrial damage (loss of ΔΨm), induction of p21CIP1, NF-κB inactivation, ROS generation, induction/phosphorylation of the stress kinase JNK accompanied by down-regulation of phospho-ERK, and marked induction of γH2A.X, indicative of double-strand DNA breaks. Bortezomib- resistant cells (e.g. SUDHL16-10BR, SUDHL6–25BR, OCI-LY10–40BR and Granta-25BR) displayed partial but relatively modest cross-resistance to CFZ administered alone. However, co-administration of CFZ/ACY-1215 sharply increased lethality in all bortezomib-resistant cells. Genetic (e.g., shRNA knockdown or ectopic expression of dominant-negative JNK) interruption of JNK signaling significantly attenuated CFZ/ACY-1215-mediated lethality. Combined treatment with CFZ and ACY-1215 inhibitors triggered marked G2M arrest but did not induce further inhibition of proteasomal activity (CT-L) compared to CFZ treatment alone. However, ACY-1215/CFZ down-regulated the cargo protein HR23B, which is essential for shuttling ubiquitinated protein to the proteasome for degradation, potentially leading to protein overload and resulting lethality. Collectively, these findings indicate that combining the selective HDAC6 inhibitor ACY-1215 with CFZ synergistically induces apoptosis in multiple DLBCL and MCL cells through a JNK-dependent process in association with G2M arrest, down-regulation of HR23B, and induction of DNA damage. They also suggest that this strategy, which is active against sensitive as well as, bortezomib-resistant DLBCL and MCL cells, warrants further exploration in NHL. Supported by Lymphoma SPORE 1P50 CA130805. Disclosures: Off Label Use: We are investigating the pre-clinical use of carfilzomib and ACY1215 for treatment DLBCL and mantle cell lymphoma for which they are not yet approved. Grant:Onyx pharmacuticals and Acetylon Pharmaceuticals: Research Funding." @default.
• W2587042212 created "2017-02-17" @default.
• W2587042212 creator A5007294115 @default.
• W2587042212 creator A5009574158 @default.
• W2587042212 creator A5038526399 @default.
• W2587042212 creator A5041310734 @default.
• W2587042212 creator A5061036144 @default.
• W2587042212 creator A5070145180 @default.
• W2587042212 date "2012-11-16" @default.
• W2587042212 modified "2023-09-28" @default.
• W2587042212 title "The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib." @default.
• W2587042212 doi "https://doi.org/10.1182/blood.v120.21.2765.2765" @default.
• W2587042212 hasPublicationYear "2012" @default.
• W2587042212 type Work @default.
• W2587042212 sameAs 2587042212 @default.
• W2587042212 citedByCount "2" @default.
• W2587042212 countsByYear W25870422122013 @default.
• W2587042212 countsByYear W25870422122015 @default.
• W2587042212 crossrefType "journal-article" @default.
• W2587042212 hasAuthorship W2587042212A5007294115 @default.
• W2587042212 hasAuthorship W2587042212A5009574158 @default.
• W2587042212 hasAuthorship W2587042212A5038526399 @default.
• W2587042212 hasAuthorship W2587042212A5041310734 @default.
• W2587042212 hasAuthorship W2587042212A5061036144 @default.
• W2587042212 hasAuthorship W2587042212A5070145180 @default.
• W2587042212 hasConcept C104317684 @default.
• W2587042212 hasConcept C185592680 @default.
• W2587042212 hasConcept C203014093 @default.
• W2587042212 hasConcept C27740335 @default.
• W2587042212 hasConcept C2776262904 @default.
• W2587042212 hasConcept C2776364478 @default.
• W2587042212 hasConcept C2777478702 @default.
• W2587042212 hasConcept C2777525834 @default.
• W2587042212 hasConcept C2778305200 @default.
• W2587042212 hasConcept C2778367456 @default.
• W2587042212 hasConcept C2778506107 @default.
• W2587042212 hasConcept C2779338263 @default.
• W2587042212 hasConcept C2780108899 @default.
• W2587042212 hasConcept C502942594 @default.
• W2587042212 hasConcept C55493867 @default.
• W2587042212 hasConcept C64927066 @default.
• W2587042212 hasConcept C86803240 @default.
• W2587042212 hasConcept C95444343 @default.
• W2587042212 hasConcept C98274493 @default.
• W2587042212 hasConceptScore W2587042212C104317684 @default.
• W2587042212 hasConceptScore W2587042212C185592680 @default.
• W2587042212 hasConceptScore W2587042212C203014093 @default.
• W2587042212 hasConceptScore W2587042212C27740335 @default.
• W2587042212 hasConceptScore W2587042212C2776262904 @default.
• W2587042212 hasConceptScore W2587042212C2776364478 @default.
• W2587042212 hasConceptScore W2587042212C2777478702 @default.
• W2587042212 hasConceptScore W2587042212C2777525834 @default.
• W2587042212 hasConceptScore W2587042212C2778305200 @default.
• W2587042212 hasConceptScore W2587042212C2778367456 @default.
• W2587042212 hasConceptScore W2587042212C2778506107 @default.
• W2587042212 hasConceptScore W2587042212C2779338263 @default.
• W2587042212 hasConceptScore W2587042212C2780108899 @default.
• W2587042212 hasConceptScore W2587042212C502942594 @default.
• W2587042212 hasConceptScore W2587042212C55493867 @default.
• W2587042212 hasConceptScore W2587042212C64927066 @default.
• W2587042212 hasConceptScore W2587042212C86803240 @default.
• W2587042212 hasConceptScore W2587042212C95444343 @default.
• W2587042212 hasConceptScore W2587042212C98274493 @default.
• W2587042212 hasLocation W25870422121 @default.
• W2587042212 hasOpenAccess W2587042212 @default.
• W2587042212 hasPrimaryLocation W25870422121 @default.
• W2587042212 hasRelatedWork W2023286508 @default.
• W2587042212 hasRelatedWork W2028820057 @default.
• W2587042212 hasRelatedWork W2041622856 @default.
• W2587042212 hasRelatedWork W2047542386 @default.
• W2587042212 hasRelatedWork W2053004448 @default.
• W2587042212 hasRelatedWork W2071361048 @default.
• W2587042212 hasRelatedWork W2133590787 @default.
• W2587042212 hasRelatedWork W2552277272 @default.
• W2587042212 hasRelatedWork W2558147844 @default.
• W2587042212 hasRelatedWork W2558207455 @default.
• W2587042212 hasRelatedWork W2558564545 @default.
• W2587042212 hasRelatedWork W2587572697 @default.
• W2587042212 hasRelatedWork W2594499083 @default.
• W2587042212 hasRelatedWork W2605481135 @default.
• W2587042212 hasRelatedWork W2912162934 @default.
• W2587042212 hasRelatedWork W2977690683 @default.
• W2587042212 hasRelatedWork W2979457211 @default.
• W2587042212 hasRelatedWork W2979615158 @default.
• W2587042212 hasRelatedWork W2980802867 @default.
• W2587042212 hasRelatedWork W3081204780 @default.
• W2587042212 isParatext "false" @default.
• W2587042212 isRetracted "false" @default.
• W2587042212 magId "2587042212" @default.
• W2587042212 workType "article" @default.